Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ilumya Becomes Sun's New Branded Specialty Drug Pillar

Executive Summary

FDA approved Ilumya for moderate to severe plaque psoriasis, furthering the competitive dynamics in the crowded psoriasis market, and establishing the biologic as a major pillar of Sun's new branded specialty drug business.

Advertisement

Related Content

As AbbVie's Risankizumab Looms, Sun Pushes To 'Maximize Time' Of Ilumya
Tildrakizumab Set For Europe Debut - Can It Make A Dent?
Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety
It's No Cosentyx/Taltz But Ilumya Pleases Customers, Says Sun
Lilly's Taltz Gets Closer To A Level Playing Field With Novartis' Cosentyx
Almirall To Put More Skin In The Game With Derma Buys
Celgene's Terrie Curran On Building, Broadening The I&I Franchise
AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount
Sun Plunges To Quarterly Loss, Outlook Challenging
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100615

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel